William W. Tseng, MD, discusses the significance of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.
William W. Tseng, MD, a sarcoma surgeon with Keck Medicine of the University of Southern California, discusses the significance of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) analysis in retroperitoneal sarcoma (RPS).
In the exploratory TARPSWG analysis, patients with high-risk RPS demonstrated a modest response to neoadjuvant systemic therapy, says Tseng. For example, partial responses were reported in about 23% of patients, and56% experienced stable disease.
Based on published literature, some controversy remains with regard to the utility of systemic therapy, particularly chemotherapy, in the sarcoma space, Tseng explains. However, these data chemotherapy has activity in this rare sarcoma subtype.
Ultimately, additional research is needed to elucidate the role of chemotherapy in this space, Tseng concludes.